ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ViewRay, Inc. (NASDAQ: VRAY) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022. Chief Financial Officer Zach Stassen and VP of Clinical Affairs Paul Strong will host a virtual fireside chat at 3:00 p.m. Eastern Time. The conference is exclusive to BTIG clients, and interested parties should contact their BTIG representative to attend. ViewRay designs and markets the MRIdian MR-Guided Radiation Therapy System, addressing unique challenges in advanced radiation oncology.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was +0.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Zach Stassen, Chief Financial Officer, and Paul Strong VP, Clinical Affairs, will participate in a virtual fireside chat at 3:00 p.m. Eastern Time on Thursday, February 17, 2022. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-to-participate-in-the-btig-medtech-digital-health-life-science--diagnostic-tools-conference-301479502.html
SOURCE ViewRay, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.